Businesses See Little Return on AI Investment, Report Finds
Despite high AI adoption rates, few businesses are seeing a return on investment. That is the key finding of the “AI at Work Index 2026” released by 5W,…
Despite high AI adoption rates, few businesses are seeing a return on investment. That is the key finding of the “AI at Work Index 2026” released by 5W,…
This edition of International People Moves details appointments at Specialty MGA and United Insurance Brokers (UIB). A summary of these new hires follows here. Specialty MGA Taps Marsh’s Smithson to…
NEW ORLEANS — Petrelintide, an investigational long-acting amylin analog, induced significant weight loss with minimal side effects in the global phase II ZUPREME-1 study. By week 28, all five investigational…
LOUISVILLE, KY.—The Neuro-Optometric Rehabilitation Association International (NORA) has opened registration for its 2026 Annual Conference, taking place October 22–25, 2026, at the Hilton Peachtree City Atlanta Hotel &…
COLOGNE, Germany: The International Dental Show (IDS) is already seeing strong demand for its 2027 edition. Shortly after exhibitor registration opened, around 1,000 companies from over 50 countries and representing key segments…
Jules Netherland traveled from her home in the Bronx to the New York state Capitol in Albany several times in the past few years, hoping to persuade the legislature to…
Merck & Co. says it will settle a spate of lawsuits that blame the drugmaker’s blockbuster Gardasil cancer vaccine for causing autoimmune ailments that affect young women’s hearts and reproductive…
Kleinstreuer to lead NIH strategic initiatives division Kleinstreuer leads the DPCPSI within the NIH Office of the Director. (Photo courtesy of NIH) Nicole Kleinstreuer, Ph.D., was recently selected to lead…
ALEXANDRIA, Va.—Following the U.S. Supreme Court’s February decision, which limited the presidential authority to impose tariffs under the International Emergency Economic Powers Act (IEEPA), the President subsequently imposed…
NEW ORLEANS — Once-daily orforglipron (Foundayo) improved outcomes in adults with type 2 diabetes and inadequate glycemic control, the international ACHIEVE-5 trial showed. In patients already taking background insulin glargine,…